Imagion Secures Growth Funding
March 7, 2023
Highlights: Imagion secures a funding facility of up to $15 million to support next phase of clinical and oncology pipeline development Funding Facility includes: $1.5 million
Press & Media Coverage
Catch up on our latest press coverage
Imagion Receives 2nd CSIRO Federal Government Grant for Prostate Cancer Project
March 1, 2023
MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, is pleased to announce that it
Imagion Biosystems 2022 Annual Report
February 28, 2023
Imagion Biosystems has released its Annual Report for the year ending 31 December 2022. [See linked documents below] 2022 Research & Development Highlights: March 2022
Biotech Daily — Dr Boreham’s Crucible: Imagion Biosystems
February 10, 2023
Tim Boreham has taken another look at Imagion Biosystems in his latest “Dr. Boreham’s Crucible” column on Biotech Daily. In the column, Tim discusses the
Biotech Daily — Imagion Trial Review Backs Magsense for All Cancer MRI
February 6, 2023
“Imagion says it will prioritize development of its Magsense nanoparticle technology as imaging agents for mainstream clinical magnetic resonance imaging (MRI) scanners. Imagion said that
Positive independent review sets priority path to market for MagSense® Technology
February 5, 2023
https://www.youtube.com/watch?v=g8SnQWwJh68 Highlights Blinded review by panel of expert breast radiologists corroborates potential for MagSense® nanoparticle technology to detect tumour cells in lymph nodes by Magnetic
Watch our latest media coverage
Transforming medical imaging for early disease detection
We’re on a mission to make cancer more detectable.